CME

Faculty: Tiffany Traina, MD, FASCO

This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.

Faculty: Tiffany Traina, MD, FASCO

This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.

Faculty: Tiffany Traina, MD, FASCO

Faculty: Javier Cortes, MD, PhD

This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.

Host: Alexandria May, PharmD, BCPS

Guest: Helena A. Yu, MD

Guest: Vicki Sherry, DNP, ANP-BC, AOCNP

Over the past two decades, advances in disease biology and precision medicine have transformed the diagnosis and treatment of non–small cell lung cancer (NSCLC). Improved understanding of NSCLC molecular drivers has led to the development of targeted therapies and immunotherapies that have enhanced disease control, symptom management, and survival for selected patients. The treatment landscape for EGFR-mutated NSCLC continues to evolve rapidly, with therapies increasingly guided by molecular profiling and histology. As treatment options expand and become more complex, members of the oncology team must stay current on molecular testing, emerging therapies, and toxicity management to optimize patient outcomes.

Faculty: Karen E. Anderson, MD

Faculty: Hubert H. Fernandez, MD

This Podcast Plus discussion reviews how treatment for tardive dyskinesia can be individualized based on patient-specific goals and pharmacologic considerations. The program examines clinically relevant differences among VMAT2 inhibitors, including factors such as speed of response, durability, tolerability, and regimen simplicity. It also addresses treatment selection in the setting of polypharmacy, with attention to CYP2D6 and CYP3A4 interactions, dose limitations, titration, and practical issues such as insurance access. In addition, the discussion highlights follow-up considerations after treatment initiation, including assessment of response, tolerability, and patient satisfaction, to support ongoing management decisions in clinical practice.

Faculty: Brendon Neuen, MBBS, PhD

Faculty: Katherine Tuttle, MD

A growing body of evidence presented at ERA 2026 is reshaping the conversation around chronic kidney disease management, regardless of diabetes status. In this expert interview, Dr. Katherine Tuttle and Dr. Brendon Neuen examine emerging data on nonsteroidal mineralocorticoid receptor antagonists and discuss how recent findings may expand treatment considerations for patients with chronic kidney disease (CKD), including those without diabetes. Through expert analysis of key studies and a patient perspective, the faculty explore the evolving cardiorenal landscape, practical implications for clinical practice, and opportunities to address persistent unmet needs across the CKD spectrum.

Faculty: Roger McIntyre, MD

Faculty: Emmanuel Mignot, MD, PhD

Sleep and psychiatric disorders are often managed separately in clinical practice, leaving key biological mechanisms unaddressed and contributing to recurrent cycles of relapse. Overlapping factors, including orexin-driven arousal mechanisms, REM sleep abnormalities, limited use of validated screening tools, and incomplete differential diagnoses for hypersomnia, can further impair quality of life and outcomes. This broadcast replay will help improve clinicians' understanding of the biological link between sleep regulation and mood dysregulation, better known as the orexin system, to support a shift from fragmented, symptom-based management to integrated, mechanism-driven care.

Host: Jörg Latus, MD

Faculty: Sayna Norouzi, MD

Focal segmental glomerulosclerosis (FSGS) remains a challenging disease, with many patients progressing to kidney failure and experiencing substantial effects on quality of life. As the treatment landscape evolves, clinicians must understand how emerging therapies may influence disease management and patient outcomes.

Join Drs. Jörg Latus and Sayna Norouzi as they review the latest evidence in FSGS, including clinical data supporting the use of sparsentan in adult and pediatric patients aged 8 years and older with FSGS without nephrotic syndrome. The faculty will explore practical considerations for treatment selection, monitoring, and long-term disease management.

Faculty: Jose Rubio, MD

Although dopamine D₂ receptor antagonists have long been the standard treatment for schizophrenia, many patients experience inadequate symptom control or adverse effects that affect adherence. Emerging evidence supports a role for muscarinic M₁/M₄ receptor dysfunction in schizophrenia, leading to the development of therapies with mechanisms distinct from dopamine blockade. This Chairperson’s Perspective reviews clinical data for xanomeline–trospium and discusses practical considerations for integrating muscarinic therapies into practice, including patient selection, treatment sequencing, dosing, and management of gastrointestinal and autonomic adverse effects. Are you prepared to incorporate muscarinic agents into the treatment of schizophrenia? Tune in for an overview of the latest data.

Guest: Emma Guttman, MD, PhD

Emma Guttman, MD, PhD, discusses the disconnect that sometimes exists in atopic dermatitis between clinical trials and real-world situations.